Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME
- PMID: 16222784
- DOI: 10.1007/s10928-005-5911-1
Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME
Abstract
In this paper, the two non-linear mixed-effects programs NONMEM and NLME were compared for their use in population pharmacokinetic/pharmacodynamic (PK/PD) modelling. We have described the first-order conditional estimation (FOCE) method as implemented in NONMEM and the alternating algorithm in NLME proposed by Lindstrom and Bates. The two programs were tested using clinical PK/PD data of a new gonadotropin-releasing hormone (GnRH) antagonist degarelix currently being developed for prostate cancer treatment. The pharmacokinetics of intravenous administered degarelix was analysed using a three compartment model while the pharmacodynamics was analysed using a turnover model with a pool compartment. The results indicated that the two algorithms produce consistent parameter estimates. The bias and precision of the two algorithms were further investigated using a parametric bootstrap procedure which showed that NONMEM produced more accurate results than NLME together with the nlmeODE package for this specific study.
Similar articles
-
Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.J Pharmacokinet Pharmacodyn. 2006 Oct;33(5):609-34. doi: 10.1007/s10928-006-9025-1. Epub 2006 Aug 8. J Pharmacokinet Pharmacodyn. 2006. PMID: 16967346
-
Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.Comput Methods Programs Biomed. 2004 Oct;76(1):31-40. doi: 10.1016/j.cmpb.2004.01.001. Comput Methods Programs Biomed. 2004. PMID: 15313540
-
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003. Clin Pharmacokinet. 2006. PMID: 16584284
-
Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.Clin Ther. 2009;31 Pt 2:2312-31. doi: 10.1016/j.clinthera.2009.11.009. Clin Ther. 2009. PMID: 20110043 Review.
-
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.AAPS J. 2007 Mar 2;9(1):E60-83. doi: 10.1208/aapsj0901007. AAPS J. 2007. PMID: 17408237 Free PMC article. Review.
Cited by
-
Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.J Pharmacokinet Pharmacodyn. 2006 Oct;33(5):609-34. doi: 10.1007/s10928-006-9025-1. Epub 2006 Aug 8. J Pharmacokinet Pharmacodyn. 2006. PMID: 16967346
-
Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.Clin Pharmacokinet. 2008;47(8):487-513. doi: 10.2165/00003088-200847080-00001. Clin Pharmacokinet. 2008. PMID: 18611060 Review.
-
Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Clin Pharmacokinet. 2013 Oct;52(10):855-68. doi: 10.1007/s40262-013-0079-0. Clin Pharmacokinet. 2013. PMID: 23719681 Review.
-
Semiparametric mixed-effects analysis of PK/PD models using differential equations.J Pharmacokinet Pharmacodyn. 2008 Aug;35(4):443-63. doi: 10.1007/s10928-008-9096-2. Epub 2008 Sep 10. J Pharmacokinet Pharmacodyn. 2008. PMID: 18781382
-
Degarelix.Drugs. 2009 Oct 1;69(14):1967-76. doi: 10.2165/10484080-000000000-00000. Drugs. 2009. PMID: 19747011
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources